Forest Hills Technologies Center

Forest Hills Lab is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapies for neurodegenerative and lysosomal storage disorders. The company's lead program, FHL-301, is a small molecule glucocerebrosidase (GCase) activator designed to enhance lysosomal function and clear protein aggregates associated with Parkinson's disease. Currently in Phase 2 development, FHL-301 represents a potential disease-modifying approach for patients with GBA-mutated Parkinson's. Forest Hills Lab operates out of its specialized facility, the Forest Hills Technologies Center, in New York. The company focuses on high-unmet-need indications including Alzheimer's and Gaucher disease. By targeting the underlying biological drivers of proteinopathy, Forest Hills Lab aims to transform the treatment landscape for aging-related brain diseases.